Dr Joseph Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center in Phoenix, USA. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF) and serves as a Councillor on the ASH Executive Committee.
Dr Mikhael specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. He is the Principal Investigator for many clinical trials, primarily in relapsed multiple myeloma, and his other clinical research interests include pharmaco-economics, communication skills, and media relations. Dr Mikhael has published over 150 peer-reviewed articles in these fields and lectures internationally on a regular basis. Dr Mikhael recently led the first ever ASCO Guidelines in multiple myeloma and serves on the editorial board of the Journal of Clinical Oncology.
Dr Mikhael is deeply involved in training future researchers and acts as a mentor to junior faculty worldwide. He now spends nearly 20% of his time in the third world developing collaborations in myeloma and finding ways to enhance access to novel agents.